Decision: Favourable

Study Title:

A Phase 3, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr Patrick Hayden

  • PI Institution:

    St James' Hospital

  • Sponsor:

    Celgene Corporation

Scroll to Top
Skip to content